Turn Therapeutics Common Stock Performance
| TTRX Stock | 3.51 0.08 2.23% |
On a scale of 0 to 100, Turn Therapeutics holds a performance score of 5. The entity has a beta of 2.03, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Turn Therapeutics will likely underperform. Please check Turn Therapeutics' skewness, day typical price, and the relationship between the downside variance and daily balance of power , to make a quick decision on whether Turn Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Turn Therapeutics Common are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Turn Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.09) | Five Day Return (12.03) | Year To Date Return (25.16) | Ten Year Return (49.86) | All Time Return (49.86) |
1 | Turn Therapeutics Coverage Initiated at D. Boral Capital | 12/29/2025 |
2 | Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences | 02/09/2026 |
| Begin Period Cash Flow | 1.2 M | |
| End Period Cash Flow | 872.6 K | |
| Total Cashflows From Investing Activities | -99.5 K |
Turn Therapeutics Relative Risk vs. Return Landscape
If you would invest 297.00 in Turn Therapeutics Common on November 18, 2025 and sell it today you would earn a total of 54.00 from holding Turn Therapeutics Common or generate 18.18% return on investment over 90 days. Turn Therapeutics Common is currently generating 0.5278% in daily expected returns and assumes 7.2587% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Turn, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Turn Therapeutics Target Price Odds to finish over Current Price
The tendency of Turn Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.51 | 90 days | 3.51 | about 69.15 |
Based on a normal probability distribution, the odds of Turn Therapeutics to move above the current price in 90 days from now is about 69.15 (This Turn Therapeutics Common probability density function shows the probability of Turn Stock to fall within a particular range of prices over 90 days) .
Turn Therapeutics Price Density |
| Price |
Predictive Modules for Turn Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Turn Therapeutics Common. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Turn Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Turn Therapeutics is not an exception. The market had few large corrections towards the Turn Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Turn Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Turn Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.09 | |
β | Beta against Dow Jones | 2.03 | |
σ | Overall volatility | 0.66 | |
Ir | Information ratio | -0.0039 |
Turn Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Turn Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Turn Therapeutics Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Turn Therapeutics is way too risky over 90 days horizon | |
| Turn Therapeutics appears to be risky and price may revert if volatility continues | |
| Turn Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (1.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Turn Therapeutics generates negative cash flow from operations | |
| Latest headline from finance.yahoo.com: Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences |
Turn Therapeutics Fundamentals Growth
Turn Stock prices reflect investors' perceptions of the future prospects and financial health of Turn Therapeutics, and Turn Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Turn Stock performance.
| EBITDA | (1.75 M) | ||||
| Net Income | (1.77 M) | ||||
| Cash Flow From Operations | (1.36 M) |
About Turn Therapeutics Performance
Evaluating Turn Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Turn Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Turn Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.30) | (1.36) | |
| Return On Capital Employed | (1.21) | (1.27) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | 8.97 | 9.42 |
Things to note about Turn Therapeutics Common performance evaluation
Checking the ongoing alerts about Turn Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Turn Therapeutics Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Turn Therapeutics is way too risky over 90 days horizon | |
| Turn Therapeutics appears to be risky and price may revert if volatility continues | |
| Turn Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (1.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Turn Therapeutics generates negative cash flow from operations | |
| Latest headline from finance.yahoo.com: Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences |
- Analyzing Turn Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Turn Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Turn Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Turn Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Turn Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Turn Therapeutics' stock. These opinions can provide insight into Turn Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Turn Stock Analysis
When running Turn Therapeutics' price analysis, check to measure Turn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Turn Therapeutics is operating at the current time. Most of Turn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Turn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Turn Therapeutics' price. Additionally, you may evaluate how the addition of Turn Therapeutics to your portfolios can decrease your overall portfolio volatility.